At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HDV iShares Core High Dividend ETF
Trading 12-30 14:35:56 EST
111.67
-0.92
-0.82%
High112.10Low111.12Vol489.86K
Open112.08D1 Closing112.59Amplitude0.87%
Mkt Cap10.90BTradable Cap10.90BTotal Shares97.65M
T/O54.65MT/O Rate0.50%Tradable Shares97.65M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B
GlobeNewswire  ·  12-26
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B
Hexaom SA Expands with HDV Group Acquisition
TIPRANKS  ·  12-24
Hexaom SA Expands with HDV Group Acquisition
Press Release: Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs
Dow Jones  ·  12-19
Press Release: Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
Business Wire  ·  12-13
Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
Business Wire  ·  11-19
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
Business Wire  ·  11-19
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates
GlobeNewswire  ·  11-08
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates
Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
Business Wire  ·  10-22
Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
HDV: An Inferior Alternative To SCHD
seekingalpha  ·  10-15
HDV: An Inferior Alternative To SCHD
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
Business Wire  ·  10-15
Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366
GlobeNewswire  ·  09-23
Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366
HDV: Good If You Like Dividends And Energy
seekingalpha  ·  09-14
HDV: Good If You Like Dividends And Energy
QQQ: My In-Depth Look At The Nasdaq-100 Fundamentals
seekingalpha  ·  09-11
QQQ: My In-Depth Look At The Nasdaq-100 Fundamentals
New Cryptocurrency Releases, Listings, & Presales Today – TNA Protocol, XBorg, LC.Link
CoinMarketCap  ·  08-24
New Cryptocurrency Releases, Listings, & Presales Today – TNA Protocol, XBorg, LC.Link
SCHD: Peeling Back The Many Layers Of This 3.80% Dividend Yielding ETF
seekingalpha  ·  08-21
SCHD: Peeling Back The Many Layers Of This 3.80% Dividend Yielding ETF
FDVV: A Strategic Blend Between Growth & Income
seekingalpha  ·  08-14
FDVV: A Strategic Blend Between Growth & Income
Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
GlobeNewswire  ·  08-09
Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
Why HDV Is An Effective Defense Play For Your Dividend Portfolio
seekingalpha  ·  08-07
Why HDV Is An Effective Defense Play For Your Dividend Portfolio
Allego Secures €20 Million Loan from EBRD to Boost EV Charging Infrastructure in Poland
Business Wire  ·  08-06
Allego Secures €20 Million Loan from EBRD to Boost EV Charging Infrastructure in Poland
HDV: Great Dividend ETF To Offset Market Shift
seekingalpha  ·  08-06
HDV: Great Dividend ETF To Offset Market Shift

Introduction

Company Name.
iShares Core High Dividend ETF
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Issue price:
--